| Sean Thomas Dieffenbaugher, MD | |
|
1350 S Kings Dr, Charlotte, NC 28207-2134 | |
| (704) 446-1255 | |
| Not Available |
| Full Name | Sean Thomas Dieffenbaugher |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 10 Years |
| Location | 1350 S Kings Dr, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083033971 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0102X | Surgery - Surgical Critical Care | 2020-02270 (North Carolina) | Secondary |
| 208600000X | Surgery | 2020-02270 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carolinas Medical Center/behav Health | Charlotte, NC | Hospital |
| Carolinas Medical Center-northeast | Concord, NC | Hospital |
| Atrium Health University City | Charlotte, NC | Hospital |
| Atrium Health Cleveland | Shelby, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carolinas Medical Center | 4789597477 | 735 |
| Carolinas Physicians Network Inc | 3375449655 | 1613 |
| The Charlotte-mecklenburg Hospital Authority | 2961310685 | 488 |
News Archive
Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.
Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.
Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
› Verified 7 days ago
| Entity Name | Carolinas Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774333 PECOS PAC ID: 4789597477 Enrollment ID: O20031110000116 |
News Archive
Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.
Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.
Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
› Verified 7 days ago
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437607686 PECOS PAC ID: 3375449655 Enrollment ID: O20040115000819 |
News Archive
Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.
Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.
Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
› Verified 7 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.
Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.
Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sean Thomas Dieffenbaugher, MD Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Sean Thomas Dieffenbaugher, MD 1350 S Kings Dr, Charlotte, NC 28207-2134 Ph: (704) 446-1255 |
News Archive
Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.
Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.
Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
› Verified 7 days ago
Dr. John Gordon Morrison, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2015 Randolph Rd, Suite 201, Charlotte, NC 28207 Phone: 704-333-1259 Fax: 704-333-0371 | |
Michael Passeri, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Suite 600, Charlotte, NC 28204 Phone: 704-355-8816 | |
Jeko Metodiev Madjarov, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1237 Harding Pl, Ste 3100, Charlotte, NC 28204 Phone: 704-373-0212 | |
Jason Shade Burgess, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2001 Vail Avenue, Ste 320, Charlotte, NC 28207 Phone: 704-333-0741 Fax: 704-333-3356 | |
Toan Thiet Huynh, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1255 | |
Sara L Turner, NP Surgery Medicare: Not Enrolled in Medicare Practice Location: 1000 Blythe Blvd, Charlotte, NC 28203 Phone: 704-512-7562 Fax: 704-512-7576 | |
Robert Gordon Graper, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2915 Coltsgate Rd, Ste 103, Charlotte, NC 28211 Phone: 704-375-7111 Fax: 704-375-0444 |